Please note that UPSpace will be unavailable from Friday, 2 May at 18:00 (South African Time) until Sunday, 4 May at 20:00 due to scheduled system upgrades. We apologise for any inconvenience this may cause and appreciate your understanding.
dc.contributor.author | Sathekge, Mike Machaba![]() |
|
dc.contributor.author | Lengana, Thabo![]() |
|
dc.contributor.author | Modiselle, Moshe![]() |
|
dc.contributor.author | Vorster, Mariza![]() |
|
dc.contributor.author | Zeevaart, Jan Rijn![]() |
|
dc.contributor.author | Maes, Alex![]() |
|
dc.contributor.author | Ebenhan, Thomas![]() |
|
dc.contributor.author | Van de Wiele, Christophe![]() |
|
dc.date.accessioned | 2018-01-12T06:42:49Z | |
dc.date.available | 2018-01-12T06:42:49Z | |
dc.date.issued | 2017-04 | |
dc.description.abstract | BACKGROUND : To report on imaging findings using 68Ga-PSMAHBED- CC PET in a series of 19 breast carcinoma patients. METHODS : 68Ga-PSMA-HBED-CC PET imaging results obtained were compared to routinely performed staging examinations and analyzed as to lesion location and progesterone receptor status. RESULTS : Out of 81 tumor lesions identified, 84% were identified on 68Ga-PSMA-HBED-CC PET. 68Ga-PSMA-HBED-CC SUVmean values of distant metastases proved significantly higher (mean, 6.86, SD, 5.68) when compared to those of primary or local recurrences (mean, 2.45, SD, 2.55, p = 0.04) or involved lymph nodes (mean, 3.18, SD, 1.79, p = 0.011). SUVmean values of progesterone receptor-positive lesions proved not significantly different from progesterone receptornegative lesions. SUV values derived from FDG PET/CT, available in seven patients, and 68Ga-PSMA-HBED-CC PET/CT imaging proved weakly correlated (r = 0.407, p= 0.015). CONCLUSIONS : 68Ga-PSMA-HBED-CC PET/CT imaging in breast carcinoma confirms the reported considerable variation of PSMA expression on human solid tumors using immunohistochemistry. | en_ZA |
dc.description.department | Nuclear Medicine | en_ZA |
dc.description.librarian | am2018 | en_ZA |
dc.description.sponsorship | Department of Nuclear Medicine at University Pretoria and NECSA. | en_ZA |
dc.description.uri | https://link.springer.com/journal/259 | en_ZA |
dc.identifier.citation | Sathekge, M., Lengana, T., Modiselle, M. et al. 68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients. European Journal of Nuclear Medicine and Molecular Imaging (2017) 44: 689-694. https://doi.org/10.1007/s00259-016-3563-6. | en_ZA |
dc.identifier.issn | 1619-7070 (print) | |
dc.identifier.issn | 1619-7089 (online) | |
dc.identifier.other | 10.1007/s00259-016-3563-6 | |
dc.identifier.uri | http://hdl.handle.net/2263/63510 | |
dc.language.iso | en | en_ZA |
dc.publisher | Springer | en_ZA |
dc.rights | © The Author(s) 2016. This article is published with open access at Springerlink.com. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http:// creativecommons.org/licenses/by/4.0/). | en_ZA |
dc.subject | 68Ga-PSMA | en_ZA |
dc.subject | PET/CT | en_ZA |
dc.subject | Breast cancer | en_ZA |
dc.subject | Prostate-specific membrane antigen (PSMA) | en_ZA |
dc.subject | Positron emission tomography (PET) | en_ZA |
dc.title | 68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients | en_ZA |
dc.type | Article | en_ZA |